Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
País como asunto
Tipo del documento
Publication year range
1.
Lupus ; 27(14): 2292-2295, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30394833

RESUMEN

BACKGROUND: Nontraumatic acute transverse myelitis (ATM) can occur in response to infectious, inflammatory and vascular triggers; 1% of patients with systemic lupus erythematosus (SLE) develop ATM, but the mechanism remains unknown. OBJECTIVE: The objective of this case report is to describe a case of intrathecal formation of anticardiolipin antibodies (aCL) during SLE-related ATM. METHODS: A single patient analysis was conducted. RESULTS: A 26-year-old housewife was diagnosed with SLE at age 19. Circulating aCL antibodies were positive at diagnosis. At age 21, she developed an episode of severe sepsis. At 23 years of age she developed an episode of ATM that left her paraplegic with a D10 sensory level, from which she recovered partially. Three years later, she developed a clinical relapse of ATM. During that second episode, serum levels of aCL were within normal limits, while cerebrospinal fluid levels were increased, suggesting intrathecal production of aCL. CONCLUSION: Here, we present a case of a woman who developed relapsing SLE-related longitudinally extensive ATM in whom intrathecal formation of aCL was demonstrated, suggesting that local production and cross-recognition of nervous tissue by those autoantibodies may be myelopathic.


Asunto(s)
Anticuerpos Anticardiolipina/sangre , Lupus Eritematoso Sistémico/complicaciones , Mielitis Transversa/diagnóstico , Adulto , Encéfalo/diagnóstico por imagen , Femenino , Humanos , Imagen por Resonancia Magnética , Recurrencia , Médula Espinal/diagnóstico por imagen
2.
Lupus ; 27(8): 1279-1286, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29635997

RESUMEN

Background and objective Acute transverse myelitis (TM) is an infrequent neurological complication of systemic lupus erythematosus (SLE). Short-term outcome varies widely between cohorts. Little is known about the epidemiology and long-term functional outcome of TM associated to SLE. Methods Patients with SLE and acute TM were identified during hospital admission, visits to the Emergency Room or the Neurology Outpatient Clinic. We evaluated ambispectively those patients with SLE presenting with clinical myelopathy and corroborated with spinal MRI. Cases were divided as partial (non-paralyzing) or complete (paralyzing). We determined long-term functional outcome as well as mortality in those patients with follow-up periods of at least five years. Results We identified 35 patients (partial, n = 15; complete, n = 20) in which complete clinical and imaging data were available (26 with follow-up ≥ 5 years). Patients with complete TM were significantly older than those with partial forms. Positive antiphospholipid antibodies were observed in 80% of patients, suggesting a possible mechanistical role. Surprisingly, functional recovery at one year was in general good; however, we observed a five-year mortality of 31% because of sepsis (in 10 cases) or pulmonary embolism (in one case). Conclusions Short-term outcome of SLE-related TM is generally good, and recurrence rate is low. However, we observed a long-term fatality rate of 31% for reasons unrelated to TM, suggesting that TM is a manifestation of severe immune dysregulation and a predictor of severity and mortality in patients with SLE.


Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Mielitis Transversa/diagnóstico por imagen , Mielitis Transversa/mortalidad , Adulto , Azatioprina/uso terapéutico , Femenino , Humanos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Imagen por Resonancia Magnética , Masculino , México , Mielitis Transversa/etiología , Prednisona/uso terapéutico , Centros de Atención Terciaria , Adulto Joven
3.
Rev Gastroenterol Mex (Engl Ed) ; 88(4): 392-403, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38097433

RESUMEN

Hepatitis C virus (HCV) infection is a worldwide public health problem associated with significant morbidity and mortality. In the context of liver transplantation, the demand for organs continues to exceed the supply, prompting the consideration of using organs from HCV-positive donors in HCV-negative recipients. The introduction of direct-acting antivirals (DAAs), which have demonstrated great efficacy in eradicating the virus, has made transplantation of organs from donors with HCV infection possible. The present article provides a brief review of the current evidence on the use of organs from HCV-infected patients.


Asunto(s)
Hepatitis C Crónica , Hepatitis C , Trasplante de Hígado , Humanos , Hepacivirus , Antivirales/uso terapéutico , México , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/cirugía , Hepatitis C/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda